Cyclooxygenases inhibitors and other compounds with antiinflamatory potential in osteoarthrosis - Part I;Inhibitory cyklooksygenaz i inne zwiqzki o potencjale przeciwzapalnym w chorobie zwyrodnieniowej stawów (osteoartrozie - OA) - czȩść i

Polski Merkuriusz Lekarski

Volumn 30, Issue 175, 2011, Pages 75-81

  Dzielska Olczak, MaŁgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cyclooxygenases; Dual cyclooxygenases and 5 lipooxygenase inhibitors; Leucotriens; Licofelone; Nonselective and selective cyclooxygenases inhibitors; Osteoarthrosis; Prostaglandins

Indexed keywords

ANTIINFLAMMATORY AGENT; LICOFELONE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL; HUMAN; OSTEOARTHRITIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; HUMANS; LIPOXYGENASE INHIBITORS; OSTEOARTHRITIS; PYRROLES;

EID: 79952144183     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Bias P., Buchner A.: Licofelone-a 5-LOX, COX-1 and COX- inhibitor-is as effective as naproxen and has improved Gl tolerability in patients with osteoarthritis. Arthritis Rheum., 2003, 48 (supl.), S72.
2. Bias P., Buchner A., Klesser B. i wsp.: The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol., 2004, 99, 611-618.
3. Blanco F.J., Buchner A., Bias P.: Licofelone, an inhibitor of COX-1, COX2, and 5-LOX, is as effective as naproxen and shows improved safety during 12 weeks treatment in patients with osteoarthritis of the knee. Ann Rheum Dis., 2003, 62, 261.
4. Bombardier C., Laine L., Reicin A. i wsp.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343, 1520.
5. Brune K., Hinz B.: Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand. J. Rheumatol. 2004, 33, 1-6.
6. Dzielska-Olczak M.: Co nowego w niesterydowych lekach przeciwzapalnych? Pol.Merk. Lek., 2007, 138, 454-458.
7. Fiorucci S., Distrutti E., de Lima O.M. i wsp.: Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J., 2003, 17, 1171-1173.
8. Garavito R.M., DeWitt D.L.: The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochem. Biophys. Acta., 1999, 1441, 278-287.
9. Gaur K., Kori M.L., Tyagi L.K. i wsp.: Licofelone - novel analgesic and anti-inflammatory agent for osteoarthritis: An overview. Pharm Chem., 2009, 1, 67-71.
10. Gay R.E., Niedhart M., Pataky F. i wsp.: Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML 300 reduces joint destruction in adjuvant arthritis. J. Rheumatol., 2001, 28, 2060-2065.
11. Gierse J.K., McDonald, Rangwala SA. i wsp.: A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem., 1996, 271, 15180-15184.
12. Gyomber E., Vattay P., Szabo S., Rainsford K.D.: Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J Gastroenterol Hepatol., 1996, 11, 922-927.
13. Hinz B., Cheremina O., Brune K.: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J., 2008, 22, 383-390.
14. Jovanovic D.V., Fernandes J.C., Martel-Pelletier J. i wsp.: In vivo dual Inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: supression of collagenase-1 and interleukin-1 beta synthesis. Arthritis Rheum., 2001, 44, 2320-2330.
15. Kraemer S.A., Meade E.A., DeWitt D.L.: Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch. Biochem. Byophys., 1992, 293, 391-400.
16. Kurumbail R.G., Stevens A.M., Gierse J.K. i wsp.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 1996, 384, 644-648.
17. McGettigan P., Henry D.: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 2006, 296, 1633-1644.
18. Martel-Pelletier J.M., Lajeunesse D., Rebout P. i wsp.: Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective nonsteroidal anti-inflammatory drugs. Ann. Rheum. Dis., 2003, 62, 501-509.
19. Mysler E.: Lumiracoxib (Prexige): a new selective COX-2 inhibitor. Int. J. Clin. Pract., 2004, 58, 606-611.
20. Nowak J.Z.: Przeciwzapalne 'prowygaszenlowe' pochodne wielonienasyconych kwasów tluszczowych omega 3i omega 6. Postȩpy Hig. Med. Dośw., 2010, 64, 115-132.
21. Pavelka K., Bias P., Buchner A. i wsp.: Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with OA of the knee. Ann. Rheum. Dis., 2003, 62 (supl.1), 261.
22. Praveen Rao P.N., Knaus E.E.: Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. J. Pharm. Pharmaceut. Sci., 2008, 11, 81-110.
23. Raynauld J.P., Martel-Pelletier J., Bias P. i wsp.: Protective effects of licofelone, a 5-lipoxygenase and cycl-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann. Rheum. Dis., 2009, 68, 938-947.
24. Silverstein F.E., Faich G., Goldstein J.L. i wsp.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA, 2000, 284, 1247.
25. Tavolari S., Bonafe M., Marini M. i wsp.: Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis, 2008, 29, 371-380.
26. Wallace J.L., McKnight G.W., Keenan C.M. i wsp.: Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology, 1990, 98, 1178-1186.
27. Warner T.D., Giullano F., Vojnovic I.i wsp.: Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl. Acad. Sci. USA, 1999, 96, 7563-7568.
28. Warner T.D., Mitchell J.A.: COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-infl ammatory drugs. Lancet, 2008 , 371, 270-273.